Skip to main content
. 2017 Jun 1;27(5):403–412. doi: 10.1089/cap.2015.0146

Table 1.

Demographic and Clinical Characteristics at Baseline (Safety Population)a

  MEM-MD-57A Part 2 (Double-blind) MEM-MD-67 (Open-label extension)
Characteristic Placebo (n = 61) Mem (n = 60) Placebo/Mem (n = 50) Mem/Mem (n = 52)
Age, yearsb 8.9 ± 2.2 9.0 ± 2.2 9.1 ± 2.3 9.1 ± 2.2
Boys, n (%) 49 (80.3) 52 (86.7) 41 (82.0) 46 (88.5)
Race, n (%)
 White 49 (80.3) 50 (83.3) 42 (84.0) 44 (84.6)
 Asian 6 (9.8) 5 (8.3) 4 (8.0) 5 (9.6)
 Black 3 (4.9) 1 (1.7) 1 (2.0) 1 (1.9)
 Other 3 (4.9) 4 (6.7) 3 (6.0) 2 (3.8)
Weight group distribution, n (%)
 Group A (≥60 kg) 4 (6.6) 5 (8.3) n/a n/a
 Group B (40-59 kg) 14 (23.0) 17 (28.3) n/a n/a
 Group C (20-39 kg) 42 (68.9) 37 (61.7) n/a n/a
 Group D (<20 kg) 1 (1.6) 1 (1.7) n/a n/a
Education Status, n (%)
 Public School 48 (78.7) 48 (80.0) n/a n/a
 Private School 5 (8.2) 5 (8.3) n/a n/a
 Home School 1 (1.6) 2 (3.3) n/a n/a
 Other 6 (9.8%) 5 (8.3) n/a n/a
K-BIT2 scoreb
 IQ composite 75.7 ± 19.4 77.9 ± 23.1 75.9 ± 19.8 78.2 ± 23.8
 Verbal score 36.4 ± 19.4 37.0 ± 16.2 35.6 ± 18.2 37.4 ± 16.3
 Nonverbal score 32.1 ± 26.1 26.3 ± 18.1 31.6 ± 25.8 25.9 ± 17.8
ADOS Scoreb
 Communication 6.3 ± 2.1 6.3 ± 2.2 n/a n/a
 Social interaction 11.0 ± 2.8 10.3 ± 2.5 n/a n/a
 Total 17.3 ± 4.5 16.7 ± 4.2 n/a n/a
 SRS, Total Raw Scoreb,c 100.2 ± 21.4 101.3 ± 25.2 100.5 ± 19.7 102.2 ± 25.5
a

The safety population in trials MEM-MD-57A Part 2 and MEM-MD-67 included seven children with autism spectrum disorder who did not have autism.

b

Mean ± standard deviation.

c

MEM-MD-57A Part 2: Autism ITT population (placebo, n = 53, memantine, n = 54); MEM-MD-67: Autism safety population (placebo/memantine, n = 46; memantine/memantine, n = 47).

ADOS, Autism Diagnostic Observation Schedule; IQ, intelligence quotient; K-BIT2, Kaufman Brief Intelligence Test, Version 2; Mem, extended-release memantine; SRS, Social Responsiveness Scale.